Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00782561 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
A Phase 1 study, sponsored by Kyntra Bio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT00782561: Clinical Trial Phase 1 study, sponsored by Kyntra Bio.
NCT00782561 is a Phase 1 study that was terminated before completion, run by Kyntra Bio. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00782561, a Phase 1 study, was terminated before completion, sponsored by Kyntra Bio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental glomerulosclerosis (FSGS).
Interventions
- DRUG FG-3019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-06-18 |
| Phase | Phase 1 |
Why NCT00782561 stopped before completion
NCT00782561 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which FG-3019 is the first listed.
NCT00782561 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00782561 about?
NCT00782561 is a clinical study titled "Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)". The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental glomerulosclerosis (FSGS).
What is the current status of trial NCT00782561?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2008-04. Estimated completion is 2009-06-18.
What interventions are being tested in trial NCT00782561?
The interventions under investigation include: FG-3019 (DRUG).
Who is sponsoring clinical trial NCT00782561?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00782561's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia